Tuberculosis — metabolism and respiration in the absence of growth
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Human tuberculosis is a complex disease caused by bacterial populations that are located in discrete lesions (microenvironments) in a single host. Some of these microenvironments are conducive to replication, whereas others restrict bacterial growth without necessarily sterilizing the infecting microorganisms. The physical and biochemical milieu in these lesions is poorly defined. None of the existing animal models for tuberculosis (except perhaps non-human primates) reproduce the diversity of disease progression that is seen in humans. Nonetheless, transcriptomics and studies using bacterial mutants have led to testable hypotheses about metabolic functions that are essential for viability in the absence of replication. A complete picture of bacterial metabolism must balance reducing equivalents while maintaining an energized membrane and basic cellular processes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“M. tuberculosis harbours genes for a cytochrome c pathway consisting of a menaquinol-cytochrome c oxidoreductase termed the bc1 complex (encoded by the qcrCAB operon, complex III) and an aa3-type cytochrome c oxidase (encoded by the genes ctaBCDE, complex IV) belonging to the heme-copper respiratory oxidase family (69–71) (Table 1).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [69]
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847 · cited 1×
“tuberculosis encodes four glucose-6-phosphate dehydrogenases — two of which require NADPH as the electron donor ( zwf1 , zwf2 ), whereas fgd1 and fgd2 encode F 420 -requiring dehydrogenase”
BackgroundSelf-citationExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“However, tumour cells are able to adjust their metabolism to adapt to anaerobic condition”
BackgroundThe Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544
Nathan, C., & Shiloh, M. U. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.8841 · Cited by 1,469 · cited 1×
“3 ), whereas higher concentrations might reach other sensitive intracellular target”
BackgroundTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
McKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360
Identification of nitric oxide synthase as a protective locus against tuberculosis
MacMicking, J. D., North, R. J., LaCourse, R., Mudgett, J. S., Shah, S. K., & Nathan, C. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5243 · Cited by 1,180 · cited 1×
“tuberculosis during the chronic stage of the disease in mice is largely dependent on production of nitric oxide and other REACTIVE NITROGEN INTERMEDIATES (RNI), with decreased production of RNIs leading to reactivation of diseas”
BackgroundWayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Research works printed but not linked: 4
- Jagirdar, J. & Zagzag, D. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 323–344 (Lippincott Williams & Wilkins, Philadelphia, 2004). A good current and historical overview of the pathology of different forms of tuberculosis in humans.
- Daley, C. L. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 85–99 (Lippincott Williams & Wilkins, Philadelphia, 2004).
- Condos, R. & Rom, W. N. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 285–299 (Lippincott Williams & Wilkins, Philadelphia, 2004).
- Garay, S. M. in Tuberculosis (eds Rom, W. N. & Garay, S. M.) 345–394 (Lippincott Williams & Wilkins, Philadelphia, 2004). A review of the clinical aspects of pulmonary tuberculosis with well-documented case studies of reactivation disease.
Cited by
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
“The potential therapeutic benefits of such agents arises from the fact that the membrane is vital to both active and metabolically inactive pathogens, and quiescent bacteria, like all living cells, require some form of cellular energy and redox homeostasis to maintain cell viability, even in the absence of growt”
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
“Elucidation of the metabolic pathways required for growth and persistence of Mycobacterium tuberculosis in the mammalian lung could point to new avenues of intervention against this recalcitrant pathoge”
BackgroundPA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., et al. (2008) · Science · doi:10.1126/science.1164571 · Cited by 628
Self-citationDrain, P. K., Bajema, K. L., Dowdy, D., Dheda, K., Naidoo, K., Schumacher, S. G., Ma, S., Meermeier, E., Lewinsohn, D. M., & Sherman, D. R. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-18 · Cited by 565
Rao, S. P. S., Alonso, S., Rand, L., Dick, T., & Pethe, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711697105 · Cited by 517
“Despite being an obligate aerobe, Mtb is able to adapt to hypoxia by exiting the cell cycle and entering a quiescent state (3, 4, 6).”
BackgroundInfluentialMeropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis
Hugonnet, J.-E., Tremblay, L. W., Boshoff, H. I., Barry, C. E., & Blanchard, J. S. (2009) · Science · doi:10.1126/science.1167498 · Cited by 494
Self-citationDeb, C., Lee, C.-M., Dubey, V. S., Daniel, J., Abomoelak, B., Sirakova, T. D., Pawar, S., Rogers, L., & Kolattukudy, P. E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006077 · Cited by 440
“However, it is unlikely that any of them truly represent the human latent TB [5,6].”
BackgroundCarbon metabolism of intracellular bacterial pathogens and possible links to virulence
Eisenreich, W., Dandekar, T., Heesemann, J., & Goebel, W. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2351 · Cited by 396
“Both early and persistent stages of infection have been analyse”
BackgroundBacterial Growth and Cell Division: a Mycobacterial Perspective
Hett, E. C., & Rubin, E. J. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00028-07 · Cited by 408
The Granuloma in Tuberculosis: Dynamics of a Host–Pathogen Collusion
Ehlers, S., & Schaible, U. E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00411 · Cited by 342
Muñoz‐Elías, E. J., Upton, A. M., Cherian, J., & McKinney, J. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05155.x · Cited by 359
“tuberculosis during infection (Boshoff and Barry, 2005; Muñoz-Elías and McKinney, 2006), we reported previously that the glyoxylate cycle enzymes ICL1 and ICL2 (Fig.”
BackgroundInfluentialDiarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803899200 · Cited by 364
Marrero, J., Rhee, K. Y., Schnappinger, D., Pethe, K., & Ehrt, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000715107 · Cited by 347
“Analyses of the Mtb icl mutants suggested that fatty acids are an important carbon and energy source forMtb during infection (3, 4).”
BackgroundThe Normalcy of Dormancy: Common Themes in Microbial Quiescence
Rittershaus, E. S. C., Baek, S.-H., & Sassetti, C. M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.012 · Cited by 340
“Similarly, M. tuberculosis harbors a number of respiratory systems utilizing both oxygen and nitrate as terminal electron acceptors (Boshoff and Barry, 2005).”
The mechanism of action of PA-824: Novel insights from transcriptional profiling
Manjunatha, U., Boshoff, H. I. M., & Barry, C. E. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.3.7926 · Cited by 319
Self-citationLilienkampf, A., Mao, J., Wan, B., Wang, Y., Franzblau, S. G., & Kozikowski, A. P. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900003c · Cited by 308
Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis
Ehrt, S., Schnappinger, D., & Rhee, K. Y. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0013-4 · Cited by 296
Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., & Franzblau, S. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00055-06 · Cited by 292
“tuberculosis chemotherapy) lies in effective targeting of this phenotype (2, 6).”
BackgroundEoh, H., & Rhee, K. Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219375110 · Cited by 278
“tuberculosis in the host are complex and heterogeneous (3, 4, 7, 9, 10).”
BackgroundCarbon metabolism of intracellular bacteria
Munoz-Elias, E. J., & McKinney, J. D. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00648.x · Cited by 268
“…a variety of counter-immune effectors (Darwin et al., 2003; Hisert et al., 2004; Karakousis et al., 2004; Ng et al., 2004; Vergne et al., 2004), but the metabolic pathways and substrates utilized by M. tuberculosis at different stages of infection are largely unknown (Boshoff and Barry, 2005).”
BackgroundGengenbacher, M., Rao, S. P. S., Pethe, K., & Dick, T. (2010) · Microbiology · doi:10.1099/mic.0.033084-0 · Cited by 260
Horne, D. J., Royce, S. E., Gooze, L., Narita, M., Hopewell, P. C., Nahid, P., & Steingart, K. R. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70071-2 · Cited by 259
Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910
Lenaerts, A. J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I. M., & Basaraba, R. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-07 · Cited by 257
“In human tissues, granulomas undergoing caseous necrosis are characterized by a lack of vascularity, which may lead to decreased oxygen tension or hypoxia (8, 12).”
BackgroundSavvi, S., Warner, D. F., Kana, B. D., McKinney, J. D., Mizrahi, V., & Dawes, S. S. (2008) · Journal of Bacteriology · doi:10.1128/jb.01767-07 · Cited by 256
“In particular, glucose deficiency and an abundance of fatty acids are thought to dictate mycobacterial metabolism during infection (3, 35), consistent with the complex repertoire of genes involved in lipid metabolism in the M.”
BackgroundHypoxia: a window into Mycobacterium tuberculosis latency
Rustad, T. R., Sherrid, A. M., Minch, K. J., & Sherman, D. R. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01325.x · Cited by 252
“These observations have led to a model of TB latency and reactivation that postulates a prominent role for oxygen status (Gomez and McKinney, 2004; Boshoff and Barry, 2005; Rao et al., 2008; Via et al., 2008).”
BackgroundDrugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
Sacchettini, J. C., Rubin, E. J., & Freundlich, J. S. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1816 · Cited by 256
“Certainly, a vital part of drug development is the understanding of the physiology of growing and persistent organisms, an area in which little information is available, as reviewed elsewher”
BackgroundBordbar, A., Lewis, N. E., Schellenberger, J., Palsson, B. Ø., & Jamshidi, N. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.68 · Cited by 252
“The lack of proper experimental M. tb models that provide a mechanistic understanding of in vivo conditions hinders a better understanding of the infection process (Boshoff and Barry, 2005).”
BackgroundIdentification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis
Ioerger, T. R., O’Malley, T., Liao, R., Guinn, K. M., Hickey, M. J., Mohaideen, N., Murphy, K. C., Boshoff, H. I. M., Mizrahi, V., Rubin, E. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075245 · Cited by 241
“Intense effort has been invested in identifying “persistence” targets, or genes that are specifically essential for maintaining infection, as high-value targets for drug discovery [56].”
BackgroundSelf-citationFumarate Reductase Activity Maintains an Energized Membrane in Anaerobic Mycobacterium tuberculosis
Watanabe, S., Zimmermann, M., Goodwin, M. B., Sauer, U., Barry, C. E., & Boshoff, H. I. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002287 · Cited by 246
“tuberculosis may use alternate electron acceptors to re-oxidize reduced cofactors and maintain an energized membrane [21].”
BackgroundSelf-citationReed, M. B., Gagneux, S., DeRiemer, K., Small, P. M., & Barry, C. E. (2007) · Journal of Bacteriology · doi:10.1128/jb.01670-06 · Cited by 238
Self-citationWhy Is Long-Term Therapy Required to Cure Tuberculosis?
Connolly, L. E., Edelstein, P. H., & Ramakrishnan, L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040120 · Cited by 229
“The first step in understanding MTB phenotypic drug resistance is to address whether it is mediated by TB-specific mechanisms as has been widely postulated, or by mechanisms common to all bacteria. TB-specific models suggest that environmental conditions in specific granuloma types, in particular those associated with…”
BackgroundUnique Flexibility in Energy Metabolism Allows Mycobacteria to Combat Starvation and Hypoxia
Berney, M., & Cook, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008614 · Cited by 235
“Slow growing cells at 50% oxygen saturation subjected to hypoxia (0.6% oxygen saturation) responded by switching on oxygen scavenging cytochrome bd, proton-translocating cytochrome bc1aa3 supercomplex, another putative hydrogenase, and by substituting NAD +-dependent enzymes with ferredoxindependent enzymes thus highl…”
BackgroundInfluentialMycobacteria, metals, and the macrophage
Neyrolles, O., Wolschendorf, F., Mitra, A., & Niederweis, M. (2015) · Immunological Reviews · doi:10.1111/imr.12265 · Cited by 216
“Interestingly, mycobacteria also have a copper-independent terminal oxidase, the cytochrome bd oxidase, which is critical for adaptation to an oxygen restricted environment (155, 158, 159) in which copper ions are also the most toxic to microbes (160).”
BackgroundPhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence
Gonzalo-Asensio, J., Mostowy, S., Harders-Westerveen, J., Huygen, K., Hernández-Pando, R., Thole, J., Behr, M., Gicquel, B., & Martín, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003496 · Cited by 223
“tuberculosis switches metabolic pathways to utilise fatty acids rather than carbohydrates during persistent infection [3,4].”
BackgroundCook, G. M., Berney, M., Gebhard, S., Heinemann, M., Cox, R. A., Danilchanka, O., & Niederweis, M. (2009) · Advances in Microbial Physiology · doi:10.1016/s0065-2911(09)05502-7 · Cited by 204
Eliminating latent tuberculosis
Young, D. B., Gideon, H. P., & Wilkinson, R. J. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2009.02.005 · Cited by 220
Niebisch, A., Kabus, A., Schultz, C., Weil, B., & Bott, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512515200 · Cited by 216
Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T., & Berney, M. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0015-2013 · Cited by 212
“…c pathway consisting of a menaquinol-cytochrome c oxidoreductase termed the bc 1 complex (encoded by the qcrCAB operon, complex III) and an aa 3 -type cytochrome c oxidase (encoded by the genes ctaBCDE , complex IV) belonging to the heme-copper respiratory oxidase family (69 – 71) (Table 1).”
BackgroundSchubert, O. T., Ludwig, C., Kogadeeva, M., Zimmermann, M., Rosenberger, G., Gengenbacher, M., Gillet, L. C., Collins, B. C., Röst, H. L., Kaufmann, S. H. E., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.06.001 · Cited by 211
Kalscheuer, R., Weinrick, B., Veeraraghavan, U., Besra, G. S., & Jacobs, W. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014642108 · Cited by 207
GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosismetabolism
Beste, D. J., Hooper, T., Stewart, G., Bonde, B., Avignone-Rossa, C., Bushell, M. E., Wheeler, P., Klamt, S., Kierzek, A. M., & McFadden, J. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r89 · Cited by 207
Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions
Greening, C., Ahmed, F. H., Mohamed, A. E., Lee, B. M., Pandey, G., Warden, A. C., Scott, C., Oakeshott, J. G., Taylor, M. C., & Jackson, C. J. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00070-15 · Cited by 194
Latent tuberculosis: what the host “sees”?
Gideon, H. P., & Flynn, J. L. (2011) · Immunologic Research · doi:10.1007/s12026-011-8229-7 · Cited by 182
“These MTB are often referred to as dormant, persistent, non-replicating [38–43] However, there is very little data to support that this is actually the case, and in fact the physiologic and metabolic status of the bacilli in latent TB remains a mystery.”
BackgroundOxygen status of lung granulomas in Mycobacterium tuberculosis‐infected mice
Aly, S., Wagner, K., Keller, C., Malm, S., Malzan, A., Brandau, S., Bange, F., & Ehlers, S. (2006) · The Journal of Pathology · doi:10.1002/path.2055 · Cited by 185
“In these characteristic and highly structured inflammatory lesions, mycobacteria often reside within necrotic tissue that has no obvious supply of oxygen [4,9].”
BackgroundSelective Killing of Nonreplicating Mycobacteria
Bryk, R., Gold, B., Venugopal, A., Singh, J., Samy, R., Pupek, K., Cao, H., Popescu, C., Gurney, M., Hotha, S., et al. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.02.003 · Cited by 182
“Nonreplicating Mtb are also problematic in clinically active tuberculosis (Boshoff and Barry, 2005).”
Baker, J. J., Johnson, B. K., & Abramovitch, R. B. (2014) · Molecular Microbiology · doi:10.1111/mmi.12688 · Cited by 181
“oxygen as a terminal electron acceptor (Boshoff and Barry, 2005).”
BackgroundThe Pathology of Mycobacterium tuberculosis Infection
Sakamoto, K. (2012) · Veterinary Pathology · doi:10.1177/0300985811429313 · Cited by 223
“Mtb adapt to this environment by preferentially using fatty acids in their metabolism, slowing down active replication, and increasing cell wall thickness, entering a so-called dormant state.(26) The lesion at the primary site of implantation is termed the Ghon focus.”
BackgroundThe prokaryotic Mo/W-bisPGD enzymes family: A catalytic workhorse in bioenergetic
Grimaldi, S., Schoepp-Cothenet, B., Ceccaldi, P., Guigliarelli, B., & Magalon, A. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2013.01.011 · Cited by 160
“[313].”
Biosynthesis and Recycling of Nicotinamide Cofactors in Mycobacterium tuberculosis
Boshoff, H. I. M., Xu, X., Tahlan, K., Dowd, C. S., Pethe, K., Camacho, L. R., Park, T.-H., Yun, C.-S., Schnappinger, D., Ehrt, S., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800694200 · Cited by 159
Self-citationNew perspectives on natural products in TB drug research
Pauli, G. F., Case, R. J., Inui, T., Wang, Y., Cho, S., Fischer, N. H., & Franzblau, S. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.004 · Cited by 159
Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis
Black, P. A., Warren, R. M., Louw, G., van Helden, P. D., Victor, T. C., & Kana, B. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02293-13 · Cited by 172
Converse, P. J., Karakousis, P. C., Klinkenberg, L. G., Kesavan, A. K., Ly, L. H., Allen, S. S., Grosset, J. H. E., Jain, S. K., Lamichhane, G., Manabe, Y. C., et al. (2008) · Infection and Immunity · doi:10.1128/iai.01117-08 · Cited by 152
“The transcriptional response of bacteria to either hypoxia or NO appears to have significant, if not complete, overlap (4, 33).”
BackgroundUpton, A. M., & McKinney, J. D. (2007) · Microbiology · doi:10.1099/mic.0.2007/011726-0 · Cited by 151
Programming bulk enzyme heterojunctions for biosensor development with tetrahedral DNA framework
Song, P., Shen, J., Ye, D., Dong, B., Wang, F., Pei, H., Wang, J., Shi, J., Wang, L., Xue, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14664-8 · Cited by 150
Inhaled Drug Delivery for Tuberculosis Therapy
Muttil, P., Wang, C., & Hickey, A. J. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9957-4 · Cited by 163
Singh, R., Barry, C. E., & Boshoff, H. I. (2010) · Journal of Bacteriology · doi:10.1128/jb.01285-09 · Cited by 163
“One hypothesis is that subpopulations of bacilli reside in distinct physical niches in which only certain drugs are active because of adaptive alterations in the metabolism of the pathogen (4).”
BackgroundSelf-citationIdentification of gene targets against dormant phase Mycobacterium tuberculosis infections
Murphy, D. J., & Brown, J. R. (2007) · BMC Infectious Diseases · doi:10.1186/1471-2334-7-84 · Cited by 159
“While the murine model replicates many facets of the human immune response [9], mice do not show well-formed granulomas and lack the caseous, necrotic centers characteristic of human infection [10].”
Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion
Johnson, J. L., Hadad, D. J., Dietze, R., Maciel, E. L. N., Sewali, B. P., Gitta, P., Okwera, A., Mugerwa, R. D., Alcaneses, M. R., Quelapio, M. I., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0536oc · Cited by 147
Dhiman, R. K., Mahapatra, S., Slayden, R. A., Boyne, M. E., Lenaerts, A., Hinshaw, J. C., Angala, S. K., Chatterjee, D., Biswas, K., Narayanasamy, P., et al. (2009) · Molecular Microbiology · doi:10.1111/j.1365-2958.2009.06625.x · Cited by 146
Elks, P. M., Brizee, S., van der Vaart, M., Walmsley, S. R., van Eeden, F. J., Renshaw, S. A., & Meijer, A. H. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003789 · Cited by 147
“relative resistance of Mtb to host and pharmacological killing [6,7].”
BackgroundBeites, T., O’Brien, K. M., Tiwari, D., Engelhart, C. A., Walters, S. B., Andrews, J., Yang, H., Sutphen, M. L., Weiner, D. M., Dayao, E. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12956-2 · Cited by 150
Self-citationBerney, M., Greening, C., Conrad, R., Jacobs, W. R., & Cook, G. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407034111 · Cited by 142
“It has also been suggested, but never proven, that mycobacteria dissipate excess reductant by coupling the reoxidation of NAD(P)H to the production of H2 (14, 15, 18, 19).”
BackgroundChakraborty, P., & Kumar, A. (2019) · Microbial Cell · doi:10.15698/mic2019.02.667 · Cited by 146
“During the NRP state, Mtb cells are believed to be metabolically quiescent, but generating sufficient energy to keep the membrane energized [96, 97].”
BackgroundDrug Targets in Mycobacterial Sulfur Metabolism
Bhave, D. P., Muse, W. B., & Carroll, K. S. (2007) · Infectious Disorders - Drug Targets · doi:10.2174/187152607781001772 · Cited by 152
Yang, M., Wang, Y., Chen, Y., Cheng, Z., Gu, J., Deng, J., Bi, L., Chen, C., Mo, R., Wang, X., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.045922 · Cited by 145
“Mtb may have unique mechanisms involved in controlling metabolic flux via succinyl-CoA and protein succinylation, because it resides in humans as its only known natural host and a large part of the energy status in Mtb occurs through the interaction with the human cells (35).”
Warner, D. F., & Mizrahi, V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-05 · Cited by 159
“targeting of the intractable pathogen (22).”
Matsoso, L. G., Kana, B. D., Crellin, P. K., Lea-Smith, D. J., Pelosi, A., Powell, D., Dawes, S. S., Rubin, H., Coppel, R. L., & Mizrahi, V. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.18.6300-6308.2005 · Cited by 134
“tuberculosis that underscore the need to investigate its function and regulation at a molecular level (6).”
BackgroundHost-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review
Kiran, D., Podell, B. K., Chambers, M. A., & Basaraba, R. J. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0537-x · Cited by 146
Targeting Phenotypically Tolerant Mycobacterium tuberculosis
Gold, B. S., & Nathan, C. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0031-2016 · Cited by 140
“M. tuberculosis is not restricted to using oxygen as an electron acceptor; it can also use nitrate or fumarate (20 – 22).”
BackgroundInteraction and Modulation of Two Antagonistic Cell Wall Enzymes of Mycobacteria
Hett, E. C., Chao, M. C., & Rubin, E. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001020 · Cited by 133
“tuberculosis has the remarkable ability to survive extended periods of time under stressful conditions within the host, only to reactivate, grow, and cause a relapse into active disease [2].”
BackgroundOuellet, H., Guan, S., Johnston, J. B., Chow, E. D., Kells, P. M., Burlingame, A. L., Cox, J. S., Podust, L. M., & de Montellano, P. R. O. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07243.x · Cited by 134
“M. tuberculosis is known to switch its metabolic pathways to lipids rather than carbohydrates during infection (Schnappinger et al., 2003; Boshoff and Barry, 2005a,b).”
BackgroundLow, K. L., Rao, P. S. S., Shui, G., Bendt, A. K., Pethe, K., Dick, T., & Wenk, M. R. (2009) · Journal of Bacteriology · doi:10.1128/jb.00530-09 · Cited by 148
“tuberculosis is believed to persist in lung lesions with hypoxic environments (6, 27).”
BackgroundGlobal transcriptional response to vancomycin in Mycobacterium tuberculosis
Provvedi, R., Boldrin, F., Falciani, F., Palù, G., & Manganelli, R. (2009) · Microbiology · doi:10.1099/mic.0.024802-0 · Cited by 133
Cook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0014-2016 · Cited by 139
“Furthermore, CbdO is likely the predominant terminal oxidase under low oxygen tensions (111, 119, 129) such as those found in hypoxic granulomas (130) and may facilitate the survival of latent or persistent bacilli (131, 132).”
BackgroundHoffman, L. R., Richardson, A. R., Houston, L. S., Kulasekara, H. D., Martens-Habbena, W., Klausen, M., Burns, J. L., Stahl, D. A., Hassett, D. J., Fang, F. C., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000712 · Cited by 134
“In support of this hypothesis, the likelihood of persistent, latent infection by the respiratory pathogen Mycobacterium tuberculosis is thought to be determined in large part by the lung metabolic milieu, particularly the relative ambient concentrations of nitrogen and oxygen species [66].”
BackgroundSimple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis
Sala, C., Dhar, N., Hartkoorn, R. C., Zhang, M., Ha, Y. H., Schneider, P. A., & Cole, S. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00821-10 · Cited by 141
“These programs have to cope with the ability of the pathogen to enter the so-called dormant or latent phase (5, 6), characterized by phenotypic drug resistance (11).”
BackgroundAntituberculosis Drug Research: A Critical Overview
Beena, & Rawat, D. S. (2012) · Medicinal Research Reviews · doi:10.1002/med.21262 · Cited by 139
Nitroimidazoles for the Treatment of TB: Past, Present and Future
Mukherjee, T., & Boshoff, H. I. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.90 · Cited by 130
Self-citationMak, P. A., Rao, S. P. S., Tan, M. P., Lin, X., Chyba, J., Tay, J. A., Ng, S. H., Tan, B. H., Cherian, J., Duraiswamy, J., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb2004884 · Cited by 126
Self-citationGeluk, A., Lin, M. Y., van Meijgaarden, K. E., Leyten, E. M. S., Franken, K. L. M. C., Ottenhoff, T. H. M., & Klein, M. R. (2007) · Infection and Immunity · doi:10.1128/iai.01990-06 · Cited by 120
“tuberculosis latency antigens (7, 25), may have potential as vaccines against latent TB.”
BackgroundCho, S., Lee, H. S., & Franzblau, S. G. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2450-9_17 · Cited by 131
Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis
Jamaati, H., Mortaz, E., Pajouhi, Z., Folkerts, G., Movassaghi, M., Moloudizargari, M., Adcock, I. M., & Garssen, J. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02008 · Cited by 136
“Non-replicating cells are particularly difficult to eradicate and may be a major cause of relative treatment insensitivity and the need for long treatment periods (6–8 month) and disease relapses (Boshoff and Barry, 2005).”
Brandli, I., Papadopoulos, A., Malaga, W., Marais, D. A., Canaan, S., Thilo, L., & de Chastellier, C. (2013) · Infection and Immunity · doi:10.1128/iai.01196-13 · Cited by 125
“Because lung granulomas present a hypoxic environment (28, 29), in vitro-growing mycobacteria (M.”
BackgroundBoonyarattanakalin, S., Liu, X., Michieletti, M., Lepenies, B., & Seeberger, P. H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja806283e · Cited by 112
The Polyketide Pks1 Contributes to Biofilm Formation in Mycobacterium tuberculosis
Pang, J. M., Layre, E., Sweet, L., Sherrid, A. M., Moody, D. B., Ojha, A. K., & Sherman, D. R. (2011) · Journal of Bacteriology · doi:10.1128/jb.06304-11 · Cited by 111
Cellitti, S. E., Shaffer, J., Jones, D. H., Mukherjee, T., Gurumurthy, M., Bursulaya, B. D., Boshoff, H. I., Choi, I., Nayyar, A., Lee, Y. S., et al. (2012) · Structure · doi:10.1016/j.str.2011.11.001 · Cited by 111
Self-citationJung, J., Madan-Lala, R., Georgieva, M., Rengarajan, J., Sohaskey, C. D., Bange, F., & Robinson, C. M. (2013) · Infection and Immunity · doi:10.1128/iai.00611-13 · Cited by 123
Current perspectives in drug discovery against tuberculosis from natural products
Nguta, J. M., Appiah‐Opong, R., Nyarko, A. K., Yeboah‐Manu, D., & Addo, P. (2015) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2015.05.004 · Cited by 118
“The therapeutic challenges encountered in eradicating dormant tubercle bacilli in MTB infection is responsible for prolonged treatment of active disease [118], making TB control difficult [119].”
BackgroundNitrate Enhances the Survival of Mycobacterium tuberculosis during Inhibition of Respiration
Sohaskey, C. D. (2008) · Journal of Bacteriology · doi:10.1128/jb.01857-07 · Cited by 108
“There is growing evidence that in the human host, the availability of oxygen is limiting for Mycobacterium tuberculosis during some stages of infection (6, 29).”
BackgroundA medicinal chemists’ guide to the unique difficulties of lead optimization for tuberculosis
Dartois, V. A., & Barry, C. E. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.07.006 · Cited by 121
Self-citationLsr2 of Mycobacterium tuberculosis is a DNA-bridging protein
Chen, J. M., Ren, H., Shaw, J. E., Wang, Y. J., Li, M., Leung, A. S., Tran, V., Berbenetz, N. M., Kocíncová, D., Yip, C. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1162 · Cited by 108
“Mycobacterium tuberculosis, the causative agent of tuberculosis, is one of the most successful and deadly pathogens, owing in part to its ability to adapt to and persist in diverse host environments (22).”
BackgroundMycobacterium tuberculosis Metabolism
Warner, D. F. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021121 · Cited by 121
“From the perspective of mycobacterial metabolism, the bacilli are predicted to access glucose and triacylglycerides as primary carbon sources during early replication under aerobic conditions; thereafter the glucose-deficient macrophage environment forces a shift to the utilization of lipids (Boshoff and Barry 2005).”
BackgroundInfluentialWalter, N. D., Dolganov, G., Garcia, B. J., Worodria, W. O., Andama, A. O., Musisi, E., Ayakaka, I., Vân, T. T. T., Voskuil, M. I., de Jong, B. C., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv149 · Cited by 124
“Whether drug-tolerant Mtb phenotypes continue replication or become non-replicating is intensely debated [5, 37, 38].”
BackgroundCholesterol Metabolism Increases the Metabolic Pool of Propionate in Mycobacterium tuberculosis
Yang, X., Nesbitt, N. M., Dubnau, E., Smith, I., & Sampson, N. S. (2009) · Biochemistry · doi:10.1021/bi9005418 · Cited by 122
Tuberculosis: Back on the Immunologists' Agenda
Kaufmann, S. H. E. (2006) · Immunity · doi:10.1016/j.immuni.2006.04.003 · Cited by 103
“First, metabolically active and dormant bacteria differ in their gene expression profile, and hence different antigens need to be selected for post- and preexposure vaccination (Kaufmann, 2005; Voskuil et al., 2003; Boshoff and Barry, 2005 ).”
BackgroundInfluentialSelengut, J., & Haft, D. H. (2010) · Journal of Bacteriology · doi:10.1128/jb.00425-10 · Cited by 117
“Likely F420-dependent families TIGR03554 (FGD1) Ac Rv0407 (1) Rv0407 (1) TIGR03559 Ac, Ch, Pr Rv3520c (4) Rv3520c (4) TIGR03560 Ac, Ch, Pr, Ar Rv1855c (6) Rv1855c (6) TIGR03564 Ac (3) (3) TIGR03617 Ac, Ch, Pr Rv1360 (3) Rv1369 (3) TIGR03619 Ac, Ch, Pr, Ba Rv0791c, Rv0940c, Rv0953c, Rv2161c, Rv3079c (13) Rv2161c, Rv307…”
Natural Products, Small Molecules, and Genetics in Tuberculosis Drug Development
Gutierrez‐Lugo, M., & Bewley, C. A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070719i · Cited by 103
Kim, P., Zhang, L., Manjunatha, U. H., Singh, R., Patel, S. J., Jiřiček, J., Keller, T. H., Boshoff, H. I., Barry, C. E., & Dowd, C. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801246z · Cited by 101
Self-citation
Metadata
- Authors
- Boshoff, H. I. M., & Barry, C. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Boshoff, Helena I. M.
- Venue
- Nature Reviews Microbiology
- Published
- 2005-01
- Volume
- 3
- Issue
- 1
- Pages
- 70-80
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1973789730
- Cited by
- 448
- References
- 88
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 9 · 2021: 17 · 2020: 20 · 2019: 22 · 2018: 21 · 2017: 22 · 2016: 20 · 2015: 35 · 2014: 30 · 2013: 24 · 2012: 26
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (Z01AI000783)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis, Mycobacterium tuberculosis, bacterial metabolism, respiration, non-replicating persistence, animal models of tuberculosis, transcriptomics, bacterial mutants, reducing equivalents, membrane potential, bacterial viability
- MeSH terms
- Adaptation, Physiological, Animals, Citric Acid Cycle, Gluconeogenesis, Humans, Mycobacterium tuberculosis, Oxidation-Reduction, Oxygen Consumption, Riboflavin, Tuberculosis, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.